Stockscreener 앱 받기
21.64
2.32%
0.49
시간 외 거래:
21.64
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Chart based analysis of Travere Therapeutics Inc. trends2025 Geopolitical Influence & Intraday High Probability Alerts - Newser
Identifying reversal signals in Travere Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified - simplywall.st
Is Travere Therapeutics Inc. a good ESG investmentJuly 2025 Setups & Reliable Intraday Trade Alerts - خودرو بانک
Travere Therapeutics Inc. stock trend forecastWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
How sensitive is Travere Therapeutics Inc. to inflation2025 Analyst Calls & Daily Entry Point Trade Alerts - خودرو بانک
What is Travere Therapeutics Inc.’s book value per share2025 Market Overview & Smart Swing Trading Techniques - خودرو بانک
Can Travere Therapeutics Inc. lead its sector in growthPortfolio Performance Report & Long-Term Capital Growth Ideas - خودرو بانک
Can Travere Therapeutics Inc. rally from current levels2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Does Travere Therapeutics Inc. stock have upside surprise potentialMarket Growth Review & Fast Entry High Yield Tips - خودرو بانک
Travere Therapeutics Inc. recovery potential after sell offJuly 2025 Action & Fast Momentum Stock Entry Tips - Newser
What is the earnings history of Travere Therapeutics Inc.Price Action & Verified Momentum Watchlists - خودرو بانک
Is Travere Therapeutics Inc. trending in predictive chart modelsQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Transcript : Travere Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Will Travere Therapeutics Inc. continue its uptrendMarket Activity Summary & Daily Momentum Trading Reports - Newser
Technical analysis overview for Travere Therapeutics Inc. stockShort Setup & Accurate Technical Buy Alerts - Newser
Travere Therapeutics' Strategic Momentum in Rare Disease Innovation and Commercial Execution - AInvest
Transcript : Travere Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 02 - MarketScreener
Travere Therapeutics at Cantor Conference: Strategic Insights on FILSPARI By Investing.com - Investing.com Canada
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Price Is Right But Growth Is Lacking - 富途牛牛
Why Travere Therapeutics Inc. is moving todayWeekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Travere Therapeutics Inc. stock prediction for this weekPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Can Travere Therapeutics Inc. be the next market leaderWeekly Trade Analysis & Capital Efficient Trade Techniques - خودرو بانک
Is Travere Therapeutics Inc.’s growth already priced inExit Point & AI Forecast for Swing Trade Picks - خودرو بانک
Will Travere Therapeutics Inc. outperform small cap indexes2025 Geopolitical Influence & Safe Entry Zone Identification - خودرو بانک
How to interpret RSI for Travere Therapeutics Inc. stockMarket Trend Review & AI Driven Stock Reports - Newser
Travere Therapeutics shares rise 4.74% intraday after presenting positive long-term data for pegtibatinase at the International Congress of Inborn Errors of Metabolism. - AInvest
HC Wainwright & Co. Reiterates Buy Rating for Travere Therapeuti - GuruFocus
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism - Business Wire
Should you hold or exit Travere Therapeutics Inc. now2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Is Travere Therapeutics Inc. stock ready for a breakoutJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Earnings visualization tools for Travere Therapeutics Inc.2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Statistical indicators supporting Travere Therapeutics Inc.’s strength2025 Buyback Activity & Target Return Focused Picks - Newser
Travere Therapeutics: Strategic Positioning in Renal Disease with Near-Term Catalysts and Valuation Potential - AInvest
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Transcript : Travere Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 03 - MarketScreener
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Risk vs reward if holding onto Travere Therapeutics Inc.Trend Reversal & Consistent Growth Stock Picks - Newser
Is Travere Therapeutics Inc. reversing from oversold territoryJuly 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
Is now the right time to enter Travere Therapeutics Inc.July 2025 Spike Watch & Detailed Earnings Play Alerts - خودرو بانک
How to monitor Travere Therapeutics Inc. with trend dashboardsChart Signals & High Accuracy Swing Trade Signals - Newser
Pullback Watch: Does Travere Therapeutics Inc. have pricing powerJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - خودرو بانک
1.40%
자본화:
|
볼륨(24시간):